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in order to improve the Treatment Planning Systems (TPS) 
software, so to properly take into account not only the 
normal tissue toxicity in the target region, but also the risk 
of late complications in the whole body [1,2]. All the 
aforementioned issues underline the importance for an 
experimental effort devoted to the precise characterization 
of the neutron production gaining experimental access both 
to the emission point and production energy.  
The technical challenges posed by a neutron detector aiming 
for high detection efficiency and good backtracking precision 
will be addressed within the MONDO (MOnitor for Neutron 
Dose in hadrOntherapy) project. The MONDO main goal is to 
develop a tracking detector targeting fast and ultrafast 
secondary neutrons. 
The main interaction mechanism of fast and ultrafast 
neutrons in plastic scintillators is the elastic scattering with 
hydrogen nuclei. In case of double elastic scattering events, 
if both protons recoil are measured, the neutron energy and 
direction can be reconstructed. The tracking and energy 
resolution achievable on the two recoiling protons drive the 
neutron energy and angular resolutions. The tracker is than 
composed by matrix (10 x 10 x 20 cm3) of squared 
scintillating fiber of 0.250 mm). The fibers are used at the 
same time as target for the elastic n-p scattering of the 
impinging neutrons and as active detector for the recoiling 
protons. The light produced and collected in the fibers will 
be amplified using a triple GEM [3] and acquired using CMOS 
Single Photon Avalanche Diode arrays [4]. 
 
The neutron tracker will measure the neutron production 
yields, as a function of production angle and energy, using 
different therapeutical beams (protons, 12C ions and possibly 
4He and 16O ions).  
The MONDO project and the preliminary test of the different 
components will be presented. 
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Purpose: A growing body of evidence on cancer stem cells 
(CSC) relates their presence in tumours to poor treatment 
outcome. Symmetrical division of CSC during therapy is a key 
factor that contributes to repopulation and treatment 
failure. However, the literature lacks quantification of the 
CSC fraction and their division pattern. Head and neck 
cancers (HNC) are challenging due to high hypoxic content 
and repopulation ability by CSCs. The aim of this work was to 
quantify the symmetrical division of CSC in a hypoxic HNC 
model treated with hyperfractionated radiotherapy and 
assess tumour response as a function of the interplay 
between CSC and the hypoxic fraction.  
Methods: A Monte Carlo technique was employed to grow a 
HNC consisting of CSC, differentiated and quiescent cells. For 
a biologically realistic growth, the initial symmetrical division 
probability of CSC was 1.9%, leading to a pre-treatment CSC 
population of 5.9%. The model considers various hypoxia 
levels as a function of the mean partial oxygen tension, from 
3mmHg to 10mmHg. CSC radioresistance was established 
according to literature [1] and adapted for HNC. 
Results: Initial CSC fraction changes during treatment due to 
repopulation, radioresistance and hypoxia. Figure 1 shows 
the variation of CSC fraction during therapy for three hypoxic 
scenarios. The figure shows that in mildly hypoxic tumours (9 
mmHg) the fraction of CSCs during treatment overtakes the 
fraction of CSC in severely hypoxic ones (3 mmHg). It nearly 
appears that hypoxia keeps the CSC subpopulation under 
control. This behaviour is due to the fact that in well-
oxygenated tumors CSCs are the most resistant subpopulation 
and they outlive non-stem cells, while in hypoxic tumors 
there are hypoxic resistant subpopulations as well as CSCs, 
thus the hypoxic content and CSC fraction are intertwined. 
 
 
While hyperfractionation (1.2Gy in 70 fractions) is likely to 
be the most optimal radiotherapy schedule for advanced HNC 
[2] the model shows that if repopulation occurs via 
symmetrical division of CSCs with a probability greater than 
5%, radiotherapy as a sole agent is not efficient for hypoxic 
HNC (table 1). However, oxic HNC benefit from 
hyperfractionation even for larger probabilities of 
symmetrical division, thus an overall dose of 84Gy in two 
1.2Gy daily fractions is effective to overcome repopulation. 
Conclusions: Quantitative evaluation of CSCs and hypoxia are 
crucial for designing successful treatment regimens for 
resistant subpopulations. 
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Purpose: Despite recent advancements in radiotherapy and 
radiosurgery, significant limitations remain. Hadrontherapy, 
which has been in clinical use for more than 15 years, has 
shown remarkable effectiveness. However, it still could 
benefit from a lower impact on non-targeted tissues to allow 
its administration at higher doses. This is the reason why we 
propose a new approached called hadron minibeam radiation 
